Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00104065 | Safety and Efficacy of CG53135-05 in the Prevention of Oral Mucositis in Patients Receiving Bone Marrow Transplant | PHASE2 | COMPLETED | - | — | — | Jan 1, 2005 | Dec 1, 2005 | Mar 15, 2016 | 9 | United States |
| Name | Type | Description |
|---|---|---|
| CG53135-05, velafermin | DRUG | - |
Inclusion Criteria: * Male or female patients ages \> 18 yrs * Patients undergoing high dose chemotherapy with or without radiation therapy treatment as conditioning for autologous hematopoietic stem cell transplantation. The conditioning regimens include at least one of the following: high dose me...